Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Cash Flow (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Net Cash Flow for 3 consecutive years, with -$29.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 57.61% to -$29.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.7 million through Dec 2025, down 199.11% year-over-year, with the annual reading at -$14.7 million for FY2025, 199.11% down from the prior year.
  • Net Cash Flow hit -$29.3 million in Q4 2025 for Immunocore Holdings, down from $2.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $391.0 million in Q1 2024 to a low of -$327.7 million in Q2 2024.
  • Historically, Net Cash Flow has averaged $2.7 million across 3 years, with a median of $6.4 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 2758.78% in 2024; the steepest drop was 3304.04% in 2024.
  • Year by year, Net Cash Flow stood at -$12.3 million in 2023, then plummeted by 461.17% to -$69.0 million in 2024, then skyrocketed by 57.61% to -$29.3 million in 2025.
  • Business Quant data shows Net Cash Flow for IMCR at -$29.3 million in Q4 2025, $2.7 million in Q3 2025, and -$780000.0 in Q2 2025.